BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Illamola SM, Colom H, van Hasselt JG. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Br J Clin Pharmacol 2016;82:793-805. [PMID: 27198625 DOI: 10.1111/bcp.13016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Darlow CA, Docobo-Perez F, Farrington N, Johnson A, McEntee L, Unsworth J, Jimenez-Valverde A, Gastine S, Kolamunnage-Dona R, de Costa RMA, Ellis S, Franceschi F, Standing JF, Sharland M, Neely M, Piddock L, Das S, Hope W. Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Antimicrob Agents Chemother 2021;65:e0029321. [PMID: 33972238 DOI: 10.1128/AAC.00293-21] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
2 Nguyen AL, Johnson PN, Neely SB, Hughes KM, Sekar KC, Welliver RC Sr, Miller JL. Comparison of Amikacin Pharmacokinetics in Neonates With and Without Congenital Heart Disease. J Pediatr Pharmacol Ther 2021;26:372-8. [PMID: 34035682 DOI: 10.5863/1551-6776-26.4.372] [Reference Citation Analysis]
3 Illamola SM, Huynh HQ, Liu X, Bhakta ZN, Sherwin CM, Liou TG, Carveth H, Young DC. Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrob Agents Chemother 2018;62:e00877-18. [PMID: 30061295 DOI: 10.1128/AAC.00877-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
4 Illamola SM, Sherwin CM, van Hasselt JGC. Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet 2018;57:1217-28. [DOI: 10.1007/s40262-018-0641-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
5 De Cock PAJG, Mulla H, Desmet S, De Somer F, Mcwhinney BC, Ungerer JPJ, Moerman A, Commeyne S, Vande Walle J, Francois K, Van Hasselt JGC, De Paepe P. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery. J Antimicrob Chemother . [DOI: 10.1093/jac/dkw496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
6 Illamola SM, Colom H, van Hasselt JG. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Br J Clin Pharmacol 2016;82:793-805. [PMID: 27198625 DOI: 10.1111/bcp.13016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]